
Teva Innovative Medicine Pipeline



Pipeline is current as of November 2026

1. In collaboration with MODAG.
2. Submitted to FDA June 2026
3. In collaboration with Launch Therapeutics
4. In collaboration with Sanofi
5. Submitted to FDA January 2026

Teva innovative medicine pipeline by development stage, excluding country / regional launches of products submitted or under review in new markets.

Teva Biosimilar Franchise

Preclinical	Clinical	Under Regulatory Review	Approved	Select Commercial Biosimilar Products
TEV-'285	TEV-'292[1]	Biosimilar to Simponi® (golimumab)[1]	Ponlimsi™[5] (denosumab-adet)	Herzuma® (trastuzumab-pkrb)[6]
TEV-'289	TEV-'333[4]	Biosimilar to Simponi Aria® (golimumab)[1]	Biosimilar to Xgeva® (denosumab)[5]	Truxima® (rituximab-abbs)[6]
TEV-'295[1]	TEV-'316[4]	Biosimilar to Eylea® (aflibercept)[1]		Ranivisio® (ranibizumab)[7]
TEV-'296[1]	Bx Ocrevus[2]	Biosimilar to Xolair® (omalizumab)		Simlandi® (adalimumab-ryvk)[1]
Bx Ocrevus Zunovo[2]		Biosimilar to Entyvio® IV (vedolizumab)[1]		Epysqli® (eculizumab-aagh)[8]
Bx Ilaris®[3] (canakinumab)		Biosimilar to Entyvio® SC (vedolizumab)[1]		Selarsdi™ (ustekinumab-aekn)[1]
Bx Fasenra®[3] (benralizumab)				

Pipeline is current as of November 2026

1. In collaboration with Alvotech for the U.S. Market 2. In collaboration with Polpharma 3. In collaboration with Samsung Bioepsis 4. In collaboration with mAbxience 5. Launched regional in Europe and approved in US 6. In collaboration with Celltrion in the U.S. and Canada 7. In collaboration with BioEq in the UK (marketed as ONGAVIA®), in the EU (marketed as RANIVISIO®) and in Canada (marketed as RANOPTO®) 8. In collaboration with Samsung Bioepis in the U.S.

Teva biosimilar pipeline by development stage, excluding country / regional launches of products submitted or under review in new markets.